Details of the Drug

General Information of Drug (ID: DMVE3TK)

Drug Name
Bromocriptine
Synonyms
Bagren; Bromergocryptine; Bromocriptin; Bromocriptina; Bromocriptinum; Bromocryptin; Bromocryptine; Bromoergocriptine; Bromoergocryptine; Ergoset; Parlodel; Bromocriptine [BAN]; Bromocriptine methanesulfonate; Parlodel Snaptabs; Alti-Bromocriptine; Apo-Bromocriptine; Bromocriptina [INN-Spanish]; Bromocriptinum [INN-Latin]; CB-154; Parlodel (TN); Bromocriptine (USAN/INN); Bromocriptine [USAN:BAN:INN]; Ergocryptine, 2-bromo-(8CI); (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione; (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman; (6aR,9R)-5-Bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide; 2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-alpha-(2-methylpropyl)ergotamin-3',6',18-trione; 2-Bromo-alpha-ergocryptine; 2-Bromo-alpha-ergokryptin; 2-Bromo-alpha-ergokryptine; 2-Bromoergocryptine Methanesulfonate; 2-Bromoergokryptine
Indication
Disease Entry ICD 11 Status REF
Acromegaly 5A60.0 Approved [1]
Hyperprolactinaemia 5A60.1 Approved [1]
Parkinson disease 8A00.0 Approved [2]
Postencephalitic Parkinson disease N.A. Approved [1]
Therapeutic Class
Antiparkinson Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 654.6
Logarithm of the Partition Coefficient (xlogp) 3.8
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Elimination
2% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 2 - 8 hours [4]
Metabolism
The drug is metabolized via the liver []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.1866 micromolar/kg/day [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.8 mg/mL [3]
Chemical Identifiers
Formula
C32H40BrN5O5
IUPAC Name
(6aR,9R)-5-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
Canonical SMILES
CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O
InChI
InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1
InChIKey
OZVBMTJYIDMWIL-AYFBDAFISA-N
Cross-matching ID
PubChem CID
31101
ChEBI ID
CHEBI:3181
CAS Number
25614-03-3
DrugBank ID
DB01200
TTD ID
D06YFA
VARIDT ID
DR00550
INTEDE ID
DR0233
ACDINA ID
D00079
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Agonist [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cyclic AMP-dependent transcription factor ATF-3 (ATF3) OTC1UOHP ATF3_HUMAN Gene/Protein Processing [9]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Gene/Protein Processing [10]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Gene/Protein Processing [10]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Protein Interaction/Cellular Processes [11]
D(2) dopamine receptor (DRD2) OTBLXKEG DRD2_HUMAN Drug Response [12]
Dopamine beta-hydroxylase (DBH) OTC6I2SP DOPO_HUMAN Gene/Protein Processing [13]
Follitropin subunit beta (FSHB) OTGLS283 FSHB_HUMAN Gene/Protein Processing [14]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Gene/Protein Processing [9]
Insulin (INS) OTZ85PDU INS_HUMAN Gene/Protein Processing [15]
Lutropin subunit beta (LHB) OT5GBOVJ LSHB_HUMAN Gene/Protein Processing [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acromegaly
ICD Disease Classification 5A60.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D2 receptor (D2R) DTT DRD2 2.50E-02 -0.08 -0.49
P-glycoprotein 1 (ABCB1) DTP P-GP 9.39E-02 1.07E-01 2.80E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Bromocriptine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Dronedarone DMA8FS5 Moderate Decreased clearance of Bromocriptine due to the transporter inhibition by Dronedarone. Angina pectoris [BA40] [16]
Posaconazole DMUL5EW Moderate Decreased metabolism of Bromocriptine caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [17]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Bromocriptine caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [17]
Tucatinib DMBESUA Moderate Decreased metabolism of Bromocriptine caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [18]
Pasireotide DMHM7JS Moderate Decreased metabolism of Bromocriptine caused by Pasireotide mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [19]
Ivacaftor DMZC1HS Moderate Decreased clearance of Bromocriptine due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [20]
MK-8228 DMOB58Q Moderate Decreased metabolism of Bromocriptine caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [21]
OPC-34712 DMHG57U Moderate Antagonize the effect of Bromocriptine when combined with OPC-34712. Depression [6A70-6A7Z] [22]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Bromocriptine and Esketamine. Depression [6A70-6A7Z] [23]
Rufinamide DMWE60C Moderate Increased metabolism of Bromocriptine caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [17]
Tazemetostat DMWP1BH Moderate Increased metabolism of Bromocriptine caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [24]
Boceprevir DMBSHMF Moderate Decreased metabolism of Bromocriptine caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [25]
Telaprevir DMMRV29 Moderate Decreased metabolism of Bromocriptine caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [26]
Rifapentine DMCHV4I Moderate Increased metabolism of Bromocriptine caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [27]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Bromocriptine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [28]
Saquinavir DMG814N Moderate Decreased metabolism of Bromocriptine caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [29]
Etravirine DMGV8QU Moderate Increased metabolism of Bromocriptine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [30]
Darunavir DMN3GCH Moderate Decreased metabolism of Bromocriptine caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [31]
Retapamulin DM9JXB7 Minor Decreased metabolism of Bromocriptine caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [32]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Bromocriptine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [33]
ITI-007 DMUQ1DO Moderate Antagonize the effect of Bromocriptine when combined with ITI-007. Insomnia [7A00-7A0Z] [22]
Brigatinib DM7W94S Moderate Increased metabolism of Bromocriptine caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [34]
PF-06463922 DMKM7EW Moderate Increased metabolism of Bromocriptine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [35]
Selpercatinib DMZR15V Moderate Decreased metabolism of Bromocriptine caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [17]
Idelalisib DM602WT Moderate Decreased metabolism of Bromocriptine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [36]
IPI-145 DMWA24P Moderate Decreased metabolism of Bromocriptine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [37]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Bromocriptine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [38]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Bromocriptine and Lasmiditan. Migraine [8A80] [39]
Exjade DMHPRWG Moderate Decreased metabolism of Bromocriptine caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [40]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Bromocriptine and Flibanserin. Mood disorder [6A60-6E23] [41]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Bromocriptine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [17]
Metoclopramide DMFA5MY Moderate Additive CNS depression effects by the combination of Bromocriptine and Metoclopramide. Nausea/vomiting [MD90] [22]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Bromocriptine caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [42]
Abametapir DM2RX0I Moderate Decreased metabolism of Bromocriptine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [43]
Lanreotide acetate DMG6ZU4 Moderate Decreased metabolism of Bromocriptine caused by Lanreotide acetate mediated inhibition of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [19]
Lefamulin DME6G97 Moderate Decreased metabolism of Bromocriptine caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [44]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Bromocriptine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [45]
Levomepromazine DMIKFEL Moderate Antagonize the effect of Bromocriptine when combined with Levomepromazine. Psychotic disorder [6A20-6A25] [22]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Bromocriptine and Quetiapine. Schizophrenia [6A20] [22]
Aripiprazole DM3NUMH Moderate Antagonize the effect of Bromocriptine when combined with Aripiprazole. Schizophrenia [6A20] [22]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Bromocriptine and Iloperidone. Schizophrenia [6A20] [22]
Paliperidone DM7NPJS Moderate Antagonize the effect of Bromocriptine when combined with Paliperidone. Schizophrenia [6A20] [22]
Molindone DMAH70G Moderate Antagonize the effect of Bromocriptine when combined with Molindone. Schizophrenia [6A20] [22]
Thiothixene DMDINC4 Moderate Antagonize the effect of Bromocriptine when combined with Thiothixene. Schizophrenia [6A20] [22]
Amisulpride DMSJVAM Major Additive CNS depression effects by the combination of Bromocriptine and Amisulpride. Schizophrenia [6A20] [23]
Asenapine DMSQZE2 Moderate Antagonize the effect of Bromocriptine when combined with Asenapine. Schizophrenia [6A20] [22]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Bromocriptine caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [46]
LEE011 DMMX75K Moderate Decreased metabolism of Bromocriptine caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [47]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Bromocriptine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [48]
Trimeprazine DMEMV9D Moderate Antagonize the effect of Bromocriptine when combined with Trimeprazine. Vasomotor/allergic rhinitis [CA08] [49]
⏷ Show the Full List of 50 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Maleic acid E00418 444266 Acidulant; Buffering agent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Citric acid monohydrate E00271 22230 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Edetate disodium E00186 8759 Complexing agent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Water E00035 962 Solvent
⏷ Show the Full List of 24 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Bromocriptine 5 mg capsule 5 mg Oral Capsule Oral
Bromocriptine 2.5 mg tablet 2.5 mg Oral Tablet Oral
Bromocriptine 0.8 mg tablet 0.8 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Bromocriptine FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 35).
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Silymarin BIO-C, an extract from Silybum marianum fruits, induces hyperprolactinemia in intact female rats. Phytomedicine. 2009 Sep;16(9):839-44.
7 Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
8 Kinetics of dithionite-dependent reduction of cytochrome P450 3A4: heterogeneity of the enzyme caused by its oligomerization. Biochemistry. 2005 Oct 25;44(42):13902-13.
9 Bromocriptine methylate suppresses glial inflammation and moderates disease progression in a mouse model of amyotrophic lateral sclerosis. Exp Neurol. 2011 Nov;232(1):41-52. doi: 10.1016/j.expneurol.2011.08.001. Epub 2011 Aug 16.
10 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
11 Mechanism of interactions of alpha-naphthoflavone with cytochrome P450 3A4 explored with an engineered enzyme bearing a fluorescent probe. Biochemistry. 2007 Jan 9;46(1):106-19. doi: 10.1021/bi061944p.
12 Imaging gene-substance interactions: the effect of the DRD2 TaqIA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward. Neurosci Lett. 2006 Sep 25;405(3):196-201. doi: 10.1016/j.neulet.2006.07.030. Epub 2006 Aug 8.
13 Plasma dopamine beta hydroxylase (D.B.H.) activity in Parkinsonian patients under L-dopa, and 2-bromo-alpha-ergocriptine loading. J Neural Transm. 1979;46(1):71-8. doi: 10.1007/BF01243430.
14 Resolution of hyperprolactinaemia after bromocriptine-induced pregnancy. Lancet. 1979 Apr 7;1(8119):784-5. doi: 10.1016/s0140-6736(79)91247-9.
15 Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women. Am J Physiol Endocrinol Metab. 2006 Nov;291(5):E1038-43. doi: 10.1152/ajpendo.00567.2005. Epub 2006 Jun 27.
16 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
17 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
19 Flogstad AK, Halse J, Grass P, Abisch E, Djoseland O, Kutz K, Bodd E, Jervell J, Flgstad AK, Djseland O "A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly." J Clin Endocrinol Metab 79 (1994): 461-5. [PMID: 8045964]
20 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
21 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
22 Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
23 Cerner Multum, Inc. "Australian Product Information.".
24 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
25 Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
26 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
27 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
28 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
29 Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
30 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
31 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
32 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
33 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
34 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
35 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
36 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
37 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
38 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
39 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
40 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
41 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
42 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
43 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
44 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
45 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
46 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
47 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
48 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
49 Product Information. Norprolac (quinagolide). Ferring Inc, North York, IA.